Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China Shots: – The company has initiated a P-III ESLIM-01 trial to evaluate the efficacy and safety of HMPL-523 in 180 adult patients with ITP. The study is based on the results of the P-Ib study in patients with the same indication – The 1EPs of the study is the DRR. The 2EPs and exploratory EPs include ORR, the incidence of treatment-emergent AEs, and patient QoL improvement – Additionally, the company currently obtains all rights to HMPL-523 globally & the therapy is being evaluated in indolent…